Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal for ImmunoTherapy of Cancer

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Genetics

Show all topics

DOI

10.1136/jitc-2024-009432

License

CC-BY-NC

Other Formats

PDF